Clinical Report: Transition from Lung Adenocarcinoma to Pulmonary Giant Cell Carcinoma
Overview
This case report discusses a 71-year-old male patient with lung adenocarcinoma who developed resistance to sotorasib-targeted therapy, leading to a transformation to pulmonary giant cell carcinoma (PGCC).
Background
Pulmonary giant cell carcinoma (PGCC) is a rare and aggressive subtype of lung cancer, accounting for less than 1% of cases. The KRAS G12C mutation is a common driver in lung adenocarcinoma.
Data Highlights
No numerical data or trial data is presented in the article.
Key Findings
Transformation from lung adenocarcinoma to PGCC can occur following resistance to targeted therapy.
The patient had a KRAS G12C mutation and developed resistance to sotorasib.
Re-biopsy confirmed the transformation to PGCC.
PGCC is characterized by highly atypical tumor cells, rapid growth, and poor prognosis.
Clinical Implications
Re-biopsy may provide critical information for guiding subsequent treatment decisions.
Conclusion
This case highlights the transformation to PGCC following resistance to targeted therapy.
